Singh U, Singh B, Bellini MI. Immunosuppressive regimens and outcomes of inflammatory bowel disease patients requiring kidney transplantation. World J Transplant 2022; 12(2): 21-23 [PMID: 35211378 DOI: 10.5500/wjt.v12.i2.21]
Corresponding Author of This Article
Urvashi Singh, MBBS, MSc, Department of Surgery, Wythenshawe Hospital, Manchester University Hospitals NHS Foundation Trust, Southmoor Road, Manchester M23 9LT, United Kingdom. usingh01@qub.ac.uk
Research Domain of This Article
Surgery
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Transplant. Feb 18, 2022; 12(2): 21-23 Published online Feb 18, 2022. doi: 10.5500/wjt.v12.i2.21
Immunosuppressive regimens and outcomes of inflammatory bowel disease patients requiring kidney transplantation
Urvashi Singh, Baljit Singh, Maria Irene Bellini
Urvashi Singh, Department of Surgery, Wythenshawe Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester M23 9LT, United Kingdom
Baljit Singh, Department of Colorectal Surgery, University Hospitals Leicester, Leicester LE1 5WW, United Kingdom
Maria Irene Bellini, Department of Surgical Sciences, Sapienza University, Roma 00161, Italy
Author contributions: Singh B and Bellini MI designed the study, provided guidance regarding inflammatory bowel disease and kidney transplantation respectively and proofread the manuscript before submission; Singh U performed literature review and wrote manuscript; all authors have read and approve the final manuscript.
Conflict-of-interest statement: There is no conflict of interest to be declared by any of the authors.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Urvashi Singh, MBBS, MSc, Department of Surgery, Wythenshawe Hospital, Manchester University Hospitals NHS Foundation Trust, Southmoor Road, Manchester M23 9LT, United Kingdom. usingh01@qub.ac.uk
Received: October 5, 2021 Peer-review started: October 5, 2021 First decision: December 16, 2021 Revised: December 28, 2021 Accepted: January 20, 2022 Article in press: January 20, 2022 Published online: February 18, 2022
Abstract
Patients with inflammatory bowel disease (IBD) can develop extra-renal complications and as a result, suffer from end stage renal failure requiring kidney transplantation (KT). A brief review of available literature revealed that IBD patients undergoing KT have shorter overall survival rates compared to their controls. Literature reporting steroid regimens and survival outcomes specific to IBD and post kidney transplant are scarce and these studies have small sample sizes thus making it difficult to draw accurate conclusions. Further research is required in the form of a randomized controlled study to clarify the effect and mechanism of steroid immunosuppression on the prognosis of renal transplant recipients and explore new treatment schemes.
Core Tip: Patients with inflammatory bowel disease (IBD) can develop extra-renal complications and as a result, suffer from end stage renal failure requiring kidney transplantation (KT). A brief review of available literature revealed that IBD patients undergoing KT have shorter overall survival rates compared to their controls. We highlight through our paper, previously reported survival outcomes and immunosuppressive regimens used in this cohort of patients through a brief literature review.
